natgillin/translations-raw huggingface dataset:
As part of this contribution, the Agency leads a fiveyear collaborative European project with the goal of developing innovative methods in pharmacoepidemiology and pharmacovigilance. 
Agencija kot del tega prispevka vodi petletni, skupni evropski projekt, katerega cilj je razvoj inovativnih metod v farmakoepidemiologiji in farmakovigilanci.
Taking into account the achievements to date, the trends and changes in the Agency's environment, the following areas of focus are identified for this year's work programme: 
Ob upoštevanju dosedanjih dosežkov, teženj in sprememb v okolju agencije, bo v letošnjem delovnem programu največja pozornost namenjena naslednjim področjem:
This work will result in the provision of better and more useful information to interested parties, including the health-technologyassessment bodies. 
S tem bomo lahko zainteresiranim strankam zagotovili boljše in koristnejše informacije, vključno z organi za ocenjevanje zdravstvene tehnologije.
At the same time, the Agency's experts contribute to the Innovative Medicines Initiative (IMI) - the panEuropean work aimed at supporting innovation. 
Hkrati bodo izvedenci agencije prispevali k pobudi za inovativna zdravila (IMI), to je vseevropsko sodelovanje za zagotavljanje podpore inovacijam.
For veterinary medicines, the Agency provides input to the European Technology Platform for Global Animal Health and the Action Plan for the Community Animal Health Strategy. 
V zvezi z zdravili za uporabo v veterinarski medicini agencija sodeluje z evropsko tehnološko platformo za zdravje živali na svetovni ravni in prispeva k akcijskemu načrtu za strategijo Skupnosti za zdravstveno varstvo živali.
Further initiatives relating to provision of more information on benefit-risk assessment and rationale for decision-making will be implemented. 
Izvedene bodo dodatne pobude v zvezi z zagotavljanjem več informacij o oceni razmerja med tveganji in koristmi ter utemeljitvijo postopka sprejemanja odločitev.
The focus in 2010 will include further implementation of the European risk-management strategy (ERMS), data-quality improvement in EudraVigilance, and support to the European Network of Centres for Pharmacovigilance and Pharmacoepidemiology. 
Leta 2010 bomo poseben poudarek namenili nadaljnjemu izvajanju Evropske strategije za obvladovanje tveganja (ERMS), izboljšanju kakovosti podatkov v zbirki EudraVigilance ter podpori Evropske mreže centrov za farmakovigilanco in farmakoepidemiologijo.
Some of these areas that will influence the Agency's resource distribution in 2010 include complex interactions between the six scientific committees of the Agency, increases in post-authorisation, referral, safety-of-medicines-related activities, and provision of information. 
Nekatera od teh področij, ki bodo vplivala na razporeditev sredstev agencije v letu 2010, zajemajo zapleteno medsebojno delovanje šestih znanstvenih odborov agencije, povečanje obsega dejavnosti po izdaji dovoljenja za promet z zdravilom, napotitvenih postopkov, dejavnosti, povezanih z varnostjo zdravil, in zagotavljanje informacij.
This trend is strengthened by the increasing number and complexity of applications across most of the Agency's activities, not least those relating to the recent legislation on advanced therapy medicinal products and paediatric medicines. 
To težnjo povečujeta vedno večje število in zapletenost prijav v zvezi z večino dejavnosti agencije, pri čemer imajo pomembno vlogo tiste, ki se nanašajo na najnovejšo zakonodajo o zdravilih za napredno zdravljenje in pediatričnih zdravilih.
The Agency will launch its redesigned public website, which will provide easier access to information for patients, healthcare professionals and enterprises. 
Agencija bo objavila prenovljeno spletno stran, na kateri bodo lažje dostopne informacije za bolnike, zdravstvene delavce in podjetja.
The Agency's activities in the field of communication and transparency will see further significant development. 
Dejavnosti agencije na področju obveščanja in preglednosti bomo še dodatno izboljšali.
These include the revision of the Variations Regulation, which brings new ways of handing variations, but also has implications for the Agency's financing, and the revised Maximum Residue Limits (MRL) Regulation, which promotes MRL extrapolation and extends the scope to cover biocidal products, as well as products used under the prescribing ‘cascade'. 
Te so popravek uredbe o spremembah, ki uvaja nove načine za obravnavanje zahtevkov za spremembe, a ima tudi posledice za financiranje agencije, ter revidirana uredba o mejnih vrednostih ostankov (MRL), ki spodbuja ekstrapolacijo mejnih vrednosti ostankov in razširja obseg uredbe tako, da ta vključuje tudi biocidne pripravke in zdravila, ki se uporabljajo v okviru „hierarhije“ predpisovanja.
This transition will be managed with care, in order to ensure that any changes ensure strong participation of Member State national competent authorities in the work of the Agency. 
Ta prehod na nov sistem bomo izvedli previdno, saj želimo zagotoviti, da bodo lahko nacionalni pristojni organi držav članic v zvezi z vsemi spremembami dejavno sodelovali pri delu agencije.
The Agency will continue its contribution to an environment that stimulates innovation and availability of medicines through its core activities, such as provision of scientific advice to companies developing new medicines and implementation of the various policies supporting development of medicines. 
Agencija si bo s svojimi osnovnimi dejavnostmi še naprej prizadevala, da bi ustvarila okolje, ki spodbuja inovacije in razpoložljivost zdravil, kot sta znanstveno svetovanje farmacevtskim družbam, ki razvijajo nova zdravila, in izvajanje različnih politik, ki podpirajo razvoj zdravil.
Fields of activity include: the implementation of initiatives relating to clinical trials and manufacturing of active ingredients in China and India, and to international work-sharing activities in the field of GMP and GCP inspections; further collaboration with non-EU regulators in the context of confidentiality arrangements and mutual-recognition agreements; and contribution to international standardisation activities. 
Ta področja dejavnosti so: udejanjanje pobud v zvezi s kliničnimi preskušanji in proizvodnjo zdravilnih učinkovin na Kitajskem in v Indiji ter mednarodnimi dejavnostmi delitve dela na področju inšpekcijskih pregledov na področjih dobre proizvodne in klinične prakse; nadaljnje sodelovanje z zakonodajnimi organi v državah zunaj EU v okviru dogovorov o zaupnosti ter prispevanje k mednarodnim dejavnostim za standardizacijo.
Due to the nature of the work of the Agency, following the authorisation of new medicinal products, there is a cumulative increase in the work needed to supervise those products, carry out pharmacovigilance activities and conduct other post-authorisation tasks. 
Zaradi narave dela agencije in odobritve novih zdravil se je povečal obseg dela, ki ga zahtevajo nadzorovanje teh zdravil, izvajanje farmakovigilančnih dejavnosti in izpolnjevanje drugih nalog po tem, ko zdravila že pridobijo dovoljenje za promet.
The European Commission issued a decision on this opinion on 22-09-2016. 
Evropska komisija je o tem mnenju izdala odločbo dne 22-09-2016.
This is a procedure where one Member State (the ‘reference Member State', in this instance the UK) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Czech Republic, France and Slovakia). 
To je postopek, pri katerem ena država članica („referenčna država članica“, v tem primeru Združeno kraljestvo) oceni zdravilo z namenom odobritve dovoljenja za promet z njim, ki bo veljavno v tej državi in v drugih državah članicah (v „zadevnih državah članicah“, v tem primeru na Češkem, v Franciji in na Slovaškem).
A review of scientific literature showed variable reductions in the uptake of different forms of diclofenac when taken with food. 
Pregled znanstvene literature je pokazal spremenljiva zmanjšanja privzema različnih oblik diklofenaka, kadar se jemlje s hrano.
This is because it is recommended that this product is preferably taken with food, and food can have a big effect on the way the medicine is taken up into the body. 
Priporoča se namreč, da je to zdravilo bolje jemati s hrano, hrana pa ima lahko velik vpliv na način privzema zdravila v telo.
However, the Member States were not able to reach an agreement and the UK medicines regulatory agency referred the matter to the CHMP for arbitration on 5 February 2016. 
Ker pa države članice niso dosegle soglasja, je britanska regulativna agencija za zdravila dne 5. februarja 2016 zadevo napotila na CHMP v arbitražo.
The French and Slovakian medicines regulatory agencies considered that a bioequivalence study of the medicine taken with food was also required because it is recommended to be preferably taken with food. 
Francoska in slovaška regulativna agencija za zdravila sta menili, da je potrebna tudi bioekvivalenčna študija jemanja zdravila s hrano, saj ga je po priporočilu bolje jemati s hrano.
Based on the evaluation of currently available data and the scientific discussion within the Committee, the CHMP concluded that bioequivalence to the reference medicine when taken with food has not been shown. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v odboru je odbor CHMP zaključil, da biološka enakovrednost z referenčnim zdravilom pri jemanju s hrano ni bila dokazana.
Questions and answers on diclofenac epolamine 50 mg tablets EMA/490203/2016 Rev. 1 
Vprašanja in odgovori o diklofenak epolaminu 50 mg tablete EMA/490203/2016 Rev. 1
On 21 July 2016, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine diclofenac epolamine (50 mg tablets). 
21. julija 2016 je Evropska agencija za zdravila končala postopek arbitraže, do katerega je prišlo po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila diklofenak epolamin (50 mg tablete).
Since some prostaglandins are involved in causing pain and inflammation at sites of injury or damage in the body, reduced prostaglandin production reduces pain and inflammation. 
Ker so nekateri prostaglandini vključeni v povzročanje bolečine in vnetja na mestih telesne poškodbe, se z zmanjšano tvorbo prostaglandinov bolečina in vnetje zmanjšata.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of this product do not outweigh its risks, and the marketing authorisation cannot be granted in the United Kingdom (UK) or in the following Member States of the EU: Czech Republic, France and Slovakia. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi tega zdravila niso večje od z njim povezanih tveganj ter da se dovoljenje za promet v Združenem kraljestvu in v naslednjih državah članicah EU ne more izdati: Češka, Francija in Slovaška.
The active substance in this medicine, diclofenac, is used for relief of pain and inflammation. 
Zdravilna učinkovina v tem zdravilu, diklofenak, se uporablja za lajšanje bolečine in vnetja.
The medicine was to be marketed as Diclofenac. 
Zdravilo naj bi se tržilo pod imenom Diclofenac.
The CHMP therefore considered that the study of the medicine taken on an empty stomach only was not sufficient to show that this product is as effective as the reference medicine. 
CHMP je zato presodil, da samo študija jemanja zdravila na prazen želodec ne zadošča za dokaz, da je zdravilo tako učinkovito kot referenčno zdravilo.
Diclofenac is a ‘non-steroidal anti-inflammatory drug' (NSAID) which reduces the body's production of substances called prostaglandins. 
Diklofenak je nesteroidno protivnetno zdravilo (NSAID), ki v telesu zmanjšuje proizvodnjo snovi, imenovanih prostaglandini.
The CHMP concluded that the benefits of these diclofenac epolamine 50 mg tablets do not outweigh their risks and recommended that marketing authorisation should not be granted in the UK or in the concerned Member States. 
CHMP je zaključil, da koristi diklofenak epolamina 50 mg tablete niso večje od tveganj, in je priporočil, da se dovoljenje za promet z zdravilom v Združenem kraljestvu in zadevnih državah članicah ne izda.
The grounds for the referral were that the study performed had only shown the medicine was bioequivalent to the reference medicine when taken on an empty stomach. 
Podlaga za napotitev je bila, da je opravljena študija dokazala samo, da je zdravilo biološko enakovredno referenčnemu zdravilu, kadar se jemlje na prazen želodec.
Altergon Italia srl submitted diclofenac epolamine (50 mg tablets) to the UK medicines regulatory agency for a decentralised procedure. 
Družba Altergon Italia srl je predložila diklofenak epolamin (50 mg tablete) britanski regulativni agenciji za zdravila v decentralizirani postopek.
Questions and answers on diclofenac epolamine 50 mg tablets 
Vprašanja in odgovori o diklofenak epolaminu 50 mg tablete
Diclofenac epolamine (50 mg tablets) is a generic medicine based on a ‘reference medicine', Flector, which is authorised in France. 
Diklofenak epolamin (50 mg tablete) je generično zdravilo, proizvedeno na podlagi referenčnega zdravila Flector, ki je odobreno v Franciji.
Because diclofenac epolamine (50 mg tablets) is a generic medicine, a study has been carried out to show that it is bioequivalent to the reference medicine, Flector, which is available as diclofenac 
Ker je diklofenak epolamin (50 mg tablete) generično zdravilo, je bila opravljena študija za dokazovanje, da je biološko enakovredno referenčnemu zdravilu Flector, ki je na voljo kot diklofenak epolamin zrnca za pripravo raztopine za pitje.
Why is diclofenac epolamine (50 mg tablets) reviewed? 
Zakaj se zdravilo diklofenak epolamin (50 mg tablete) pregleduje?
What is diclofenac epolamine (50 mg tablets)? 
Kaj je zdravilo diklofenak epolamin (50 mg tablete)?
2132 HK Hoofddorp Netherlands 
2132 HK Hoofddorp Nizozemska
102 53 Stockholm Sweden 
102 53 Stockholm Švedska
4000 Roskilde 
4000 Roskilde Danska
Al. Jerozolimskie 146A 02-305 Warsaw Poland 
Al. Jerozolimskie 146A 02-305 Warsaw Poljska
Quinta da Fonte Edificio Gil Eanes Paço D´Arcos 2770-192 Paço D` Arcos Portugal 
Quinta da Fonte Edificio Gil Eanes Paço D´Arcos 2770-192 Paço D` Arcos Portugalska
176 74 Kallithea Greece 
176 74 Kallithea Grčija
Laboratórios Delta, Lda. 
Portugalska Laboratórios Delta, Lda.
Nycomed France 13, rue Watt 75013 Paris France 
Nycomed France 13, rue Watt 75013 Paris Francija
Almirall S.p.A via Messina, 38 Torre C 20154 Milan Italy 
Almirall S.p.A via Messina, 38 Torre C 20154 Milan Italija
Nycomed Pharma GmbH Euro Plaza Gebäude F Technologiestrasse 5 1120 Vienna Austria 
Nycomed Pharma GmbH Euro Plaza Gebäude F Technologiestrasse 5 1120 Vienna Avstrija
Via Temolo 4 20126 Milan Italy 
Via Temolo 4 20126 Milan Italija
Netherlands Nycomed bv Jupiterstraat 250 
Nizozemska Nycomed bv Jupiterstraas 250
Nycomed Portugal Produtos Farmaceuticos, Lda. 
Portugalska Nycomed Portugal Produtos Farmaceuticos, Lda.
Nycomed Italia S.r.l via Libero Temolo 4 20126 Milan Italy 
Nycomed Italia S.r.l via Libero Temolo 4 20126 Milan Italija
Nycomed Portugal - Produtos Farmacêuticos, Lda. 
Portugalska Nycomed Portugal - Produtos Farmacêuticos, Lda.
Luxembourg Nycomed Belgium SCA/CVA 
Luksemburg Nycomed Belgium SCA/CVA
78467 Konstance Germany 
78467 Constance Nemčija
Luxembourg Nycomed Belgium SCA/CVA Gentsesteenweg 615 
Luksemburg Nycomed Belgium SCA/CVA Gentsesteenweg 615
Hungary Nycomed GmbH Byk-Gulden-Str.2 
Madžarska Nycomed GmbH Byk-Gulden-Str.2
Nycomed GmbH Byk-Gulden-Str.2 78467 Konstance Germany 
Nycomed GmbH Byk-Gulden-Str.2 78467 Konstance Nemčija
Nycomed GmbH Byk-Gulden-Str.2 78467 Konstanz Germany 
Nycomed GmbH Byk-Gulden-Str.2 78467 Konstanz Nemčija
Somac 40 mg enterotabletti 40 mg Gastro-resistant tablet 
Somac 40 mg enterotabletti40 mg gastrorezistentna tableta peroralna uporaba
Somac 20 mg enterotabletti 20 mg Gastro-resistant tablet 
Somac 20 mg enterotabletti20 mg gastrorezistentna tableta peroralna uporaba
Pantoprazol NYC 20 mg 20 mg Gastro-resistant tablet 
Pantoprazol NYC 20 mg 20 mg gastrorezistentna tableta peroralna uporaba
Pantoprazol NYC 40 mg 40 mg Gastro-resistant tablet 
Pantoprazol NYC 40 mg 40 mg gastrorezistentna tableta peroralna uporaba
Nycomed GmbH Byk-Gulden-Str.2 78467 Constance Germany 
Madžarska Nycomed GmbH Byk-Gulden-Str.2 78467 Constance Nemčija
Belgium 
Bolgarija
Zurcal 20 mg -Filmtabletten 20 mg Gastro-resistant tablet 
Pantoprazol 20 mg Byk 20 mg gastrorezistentna tableta peroralna uporaba
Zurcal 40 mg -Filmtabletten 40 mg Gastro-resistant tablet 
Ulcotenal 40 mg Blister 40 mg gastrorezistentna tableta peroralna uporaba
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
DODATEK POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO UVESTI DRŽAVE ČLANICE
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE ADDRESSED BY THE MEMBER STATES The Member States should ensure that the MAH provides an educational programme for Remicade to ensure that physicians who intend to prescribe Remicade to paediatric Crohn's disease patients are aware of: 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO OBRAVNAVATI DRŽAVE ČLANICE Države članice morajo zagotoviti, da bo imetnik dovoljenja za promet z zdravilom pripravil izobraževalni program o zdravilu Remicade, s katerim bi zagotovili, da se bodo zdravniki, ki želijo predpisovati zdravilo Remicade pediatričnim bolnikom s Crohnovo boleznijo, dobro zavedali naslednjih stvari:
• The risk of opportunistic infections and tuberculosis (TB) in patients treated with Remicade. 
• tveganja za pojav oportunističnih okužb in tuberkuloze (TB) pri bolnikih, zdravljenih z zdravilom Remicade,
• The risk of lymphoma and other malignancies. 
• tveganja za nastanek limfoma in drugih malignih bolezni,
• The risk of acute infusion related reactions and delayed hypersensitivity reactions. 
• tveganja za pojav akutne infuzijske reakcije in poznih preobčutljivostnih reakcij,
• The need to assess the risk of TB in patients prior to treating with Remicade. 
• potrebe po oceni tveganja za obstoj TB pri bolnikih še pred zdravljenjem z zdravilom Remicade,
• The patient alert card, which is to be given to patients using Remicade. 
• da obstaja opozorilna kartica za bolnike, ki jo morajo dati vsem bolnikom, ki prejemajo zdravilo Remicade,
• That children may be at increased risk of developing infections and the need for immunisations to be up to date. 
• da se lahko pri otrocih poveča tveganje za okužbe in je treba zato pri njih opraviti vsa cepljenja v skladu s programom.
Children and adolescents Use in children and adolescents under 18 years is not recommended. 
Otroci in mladostniki Uporabe zdravila pri otrocih in mladostnikih mlajših od 18 let ne priporočamo.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. 
Pred začetkom jemanja zdravilo natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice. 
Priporočljivo je, da imat pri sebi nekaj kock sladkorja, bonbone, piškote ali sladek sadni sok.
Your doctor will check whether Pioglitazone Teva Pharma is working 3 to 6 months after you start taking it. 
Zdravnik bo preveril, ali zdravilo Pioglitazone Teva Pharma deluje, 3 do 6 mesecev po tem, ko začnete jemati zdravilo.
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. 
Pri zdravljenju bolnikov, ki imajo vsaj en dejavnik tveganja za razvoj kongestivnega srčnega popuščanja
Your blood sugar will be checked, and your dose of Pioglitazone Teva Pharma may need to be changed. 
Preverili bodo raven vašega krvnega sladkorja in vaš odmerek zdravila Pioglitazon Teva Pharma bo morda potrebno spremeniti.
Date of latest renewal: 17 February 2017 
Datum pridobitve dovoljenja za promet: 26. marec 2012 Datum zadnjega podaljšanja: 17. februar 2017
Do not use this medicine after the expiry date which is stated on the carton and the blister after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu, poleg oznake EXP.
Pioglitazone Teva Pharma helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. 
Zdravilo Pioglitazon Teva Pharma pomaga nadzorovati raven sladkorja v krvi, če imate sladkorno bolezen tipa 2, in sicer tako, da telesu pomaga bolje izkoristiti insulin, ki ga izdela.
If you take more Pioglitazone Teva Pharma than you should If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. 
Če ste vzeli večji odmerek zdravila Pioglitazon Teva Pharma, kot bi smeli Če po nesreči zaužijete preveč tablet ali če kdo drug ali otrok zaužije vaša zdravila, nemudoma obvestite svojega zdravnika ali farmacevta.
When Pioglitazone Teva Pharma is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines. 
Če boste jemali zdravilo Pioglitazon Teva Pharma skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, ali morate jemati nižje odmerke teh zdravil.
prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually. 
(npr. predhodni miokardni infarkt ali simptomatska koronarna arterijska bolezen), bi moral zdravnik začeti zdravljenje z najnižjim možnim odmerkom in ga postopoma višati.
If you take Pioglitazone Teva Pharma with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia). 
Če ste vzeli zdravilo Pioglitazon Teva Pharma z drugimi zdravili za zdravljenje sladkorne bolezni, je bolj verjetno, da vrednost vašega krvnega sladkorja pade pod normalno raven (hipoglikemija).
If you have the impression that the effect of Pioglitazone Teva Pharma is too weak, talk to your doctor. 
Če menite, da je učinek zdravila Pioglitazon Teva Pharma prešibak, se posvetujte z zdravnikom.
50 x 1 tablets in Aluminium/aluminium perforated unit dose blisters. 
50 x 1 tableta v aluminij/aluminij perforiranem pretisnem omotu za enkratni odmerek.
Other medicines and Pioglitazone Teva Pharma Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Piaglitazon Teva Pharma Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali, ali pa boste morda začeli jemati katero koli drugo zdravilo.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. 
Študije medsebojnih delovanj so pokazale, da pioglitazon nima pomembnega učinka na farmakokinetiko ali farmakodinamiko digoksina, varfarina, fenprokumona in metoformina.
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments. 
2O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri zdravljenju z drugimi hipoglikemiki.